Malignant neoplasm of breast, HER-positive (controls excluding all cancers)

C3_BREAST_ERPLUS_EXALLC

No definition available.

Endpoint definition

FinnGen phenotype data

individuals

diagram downward connector
diagram bullet

Apply sex-specific rule

Sex only females

diagram downward connector
diagram bullet

Check conditions

RX_ERPLUS

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Cause of death: ICD-10 C50
Cause of death: ICD-9 174
Cause of death: ICD-8 174
Cancer registry: Topography ICD-O-3 C50
Cancer registry: Morphology ICD-O-3 ANY
Cancer registry: Behaviour codes [23]

2 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector

Include endpoints None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

10404

diagram downward connector
C3_BREAST_ERPLUS_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE
Control conditions not RX_ERPLUS

Extra metadata

Level in the ICD hierarchy 2
First used in FinnGen datafreeze DF9

Summary Statistics

Key figures

All Female Male
Number of individuals 10404 10404 -
Unadjusted prevalence (%) 2.53 4.52 -
Mean age at first event (years) 59.23 59.23 -

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.04 2.04 [1.64, 2.53] 1.6e-10 1043
15 years 0.01 1.46 [1.22, 1.76] 5.7e-5 522
5 years 0.00 2.40 [1.98, 2.92] 5.3e-19 316
1 year 0.00 0.96 [0.62, 1.48] 8.4e-1 24

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: C3_BREAST_ERPLUS_EXALLC – Malignant neoplasm of breast, HER-positive (controls excluding all cancers)
GWS hits: 45

Survival analyses between endpoints

Plot

before Malignant neoplasm of breast, HER-positive (controls excluding all cancers)
after Malignant neoplasm of breast, HER-positive (controls excluding all cancers)

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Malignant neoplasm of breast, HER-positive (controls excluding all cancers)

Endpoint not on priority list, no data to show.